[1]侯晓玮,庄兴俊,宋 谦,等.CT引导经皮肺穿刺活检检测晚期非小细胞肺癌表皮生长因子受体基因突变[J].介入放射学杂志,2013,(02):125-128.
 HOU Xiao? wei,ZHUANG Xing? jun,SONG Qian,et al.Application of CT?蛳 guided percutaneous lung biopsy in detecting epidermal growth factor receptor gene mutations in patients with advanced non- small cell lung cancer[J].journal interventional radiology,2013,(02):125-128.
点击复制

CT引导经皮肺穿刺活检检测晚期非小细胞肺癌表皮生长因子受体基因突变()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年02期
页码:
125-128
栏目:
肿瘤介入
出版日期:
2013-02-25

文章信息/Info

Title:
Application of CT?蛳 guided percutaneous lung biopsy in detecting epidermal growth factor receptor gene mutations in patients with advanced non- small cell lung cancer
作者:
侯晓玮 庄兴俊 宋 谦 李露嘉 王宁宁
Author(s):
HOU Xiao?蛳 wei ZHUANG Xing?蛳 jun SONG Qian LI Lu?蛳 jia WANG Ning?蛳 ning.
Department of Oncology, No.401 Hospital of PLA, Qingdao, Shandong Province 266071, China
关键词:
【关键词】 非小细胞肺癌 CT引导经皮肺穿刺活检 EGFR基因突变
文献标志码:
A
摘要:
【摘要】 目的 研究CT引导经皮肺穿刺活检获得组织检测非小细胞肺癌(NSCLC)表皮生长因子受体(EGFR)基因突变的可行性。方法 入组40例晚期或局部晚期无法手术的NSCLC患者,采用18 G自动活检枪,经CT引导行肺穿刺活检获取肿瘤组织,行EGFR基因检测,观察术后并发症,分析检测结果。结果 40例病例均经穿刺活检获得足够的病变组织进行组织学诊断和基因突变检测,EGFR基因突变率为37.5%(15/40),其中腺癌患者突变率为50.0%(12/24),非腺癌患者突变率为18.8%(3/16),两者间差异有统计学意义;3例患者穿刺后出现气胸,3例患者出现咯血;无血胸、纵隔气肿、感染及针道种植等并发症;EGFR基因突变患者使用吉非替尼治疗获得良好疗效。结论 CT引导的经皮肺穿刺活检技术简便、安全,是晚期NSCLC获得肿瘤组织检测EGFR基因突变的可靠方法,能够用于预测晚期NSCLC的靶向治疗效果。

参考文献/References:

[1] Spiro SG, Porter JC. Lung cancer—where are we today? Current advances in staging and nonsurgical treatment[J]. Am J Respir Crit Care Med, 2002, 166: 1166 ?蛳 1196.[2] Datta D, Lahiri B. Preoperative evaluation of patients undergoing lung resection surgery[J]. Chest, 2003, 123: 2096 ?蛳 2103.[3] Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non?蛳 small?蛳 cell lung Cancer[J]. N Engl J Med, 2002, 346: 92 ?蛳 98.[4] Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung Cancer: correlation with clinical response to gefitinib therapy[J]. Science, 2004, 304: 1497 ?蛳 1500.[5] Brevet M, Johnson ML, Azzoli CG, et al. Detection of EGFR mutations in plasma DNA from lung Cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors[J]. Lung Cancer, 2011, 73: 96 ?蛳 102.[6] Kimura H, Kasahara K, Kawaishi M, et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non?蛳 small?蛳 cell lung Cancer[J]. Clin Cancer Res, 2006, 12: 3915 ?蛳 3921.[7] Ellis M, Davis N, Coop A, et al. Development and validation of a method for using breast core needle biopsies for gene expression microarray analyses[J]. Clin Cancer Res, 2002, 8: 1155 ?蛳 1166.[8] Chen CM, Chang JW, Cheung YC, et al. Computed tomography?蛳 guided core?蛳 needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non?蛳 small?蛳 cell lung Cancer[J]. Acta radiol, 2008, 49: 991 ?蛳 994.[9] Solomon SB, Zakowski MF, Pao W, et al. Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis[J]. Am J Roentgenol, 2010, 194: 266 ?蛳 269.[10] 庄一平, 张 晋, 史美祺, 等. CT导向肺癌穿刺标本表皮生长因子受体基因突变检测的应用价值[J]. 介入放射学杂志, 2011, 20: 276 ?蛳 278.[11] Pao W, Miller VA. Epidermal growth factor receptor mutations, small?蛳 molecule kinase inhibitors, and non?蛳 small?蛳 cell lung Cancer: current knowledge and future directions[J]. J Clin Oncol, 2005, 23: 2556 ?蛳 2568.

相似文献/References:

[1]蒲德利,廖江荣.射频消融联合化疗治疗周围型中晚期非小细胞肺癌疗效观察[J].介入放射学杂志,2013,(02):129.
 PU De? li,LIAO Jiang? rong..Radiofrequency ablation combined with GP chemotherapy for stage Ⅲ and Ⅳ peripheral non- small cell lung cancer: a clinical observation[J].journal interventional radiology,2013,(02):129.

备注/Memo

备注/Memo:
(收稿日期:2012?鄄10?鄄12)
更新日期/Last Update: